Ken Drazan, ArsenalBio CEO

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

If Ar­se­nal­Bio does it right, its first CAR-T can­di­date — a po­ten­tial treat­ment for ovar­i­an can­cer — will be in the clin­ic lat­er this year.

And a group of deep-pock­et­ed in­vestors are bet­ting $220 mil­lion that it can.

South San Fran­cis­co-based Ar­se­nal­Bio launched out of the gate in late 2019 amid a wave of ac­tiv­i­ty form­ing around cell ther­a­py 2.0, with promis­es of putting to­geth­er an “ar­se­nal” of tech­nolo­gies that can en­gi­neer cells more pre­cise­ly, in or­der to strike the per­fect bal­ance on ef­fi­ca­cy and safe­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.